Sameem Abedin, MD

Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.

Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses managing cardiac toxicities with acalabrutinib vs ibrutinib in patients with chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses frontline treatment considerations for patients with chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses the clinical significance of undetectable minimal residual disease status in chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses the need for risk stratification prior to giving chemoimmunotherapy to patients with chronic lymphocytic leukemia.

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the use of PI3K inhibitors in the treatment of patients with chronic lymphocytic leukemia (CLL).

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses the role of venetoclax plus obinutuzumab in chronic lymphocytic leukemia.

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses key updates in the treatment of patients with chronic lymphocytic leukemia.